Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × Saline Solution × Clear all

Phase

Phase 3 3 Phase 4 2 Phase NA 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomatitis 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Pain 2 Multiple Myeloma 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Fatigue 2 Carcinoma, Hepatocellular 2 Ulcer 1 Trauma, Nervous System 1 Spondylitis, Ankylosing 1 Skin Neoplasms 1 Schwannomatosis 1 Rectal Neoplasms 1 Psoriasis 1 Pleural Effusion, Malignant 1 Pancreatic Cyst 1 Ovarian Neoplasms 1 Non-functioning Pituitary Adenoma 1 Neurofibromatosis 1 1 Neurilemmoma 1 Neoplasms 1 Myelodysplastic Syndromes 1 Metastatic Non-Squamous Non-Small Cell Lung Cancer 1 Mesothelioma 1 Malignant Neoplasm of Colorectum 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma 1

Interventions

Paclitaxel 115 Carboplatin 115 Bevacizumab 76 Gemcitabine 38 pembrolizumab 36 olaparib 32 Cisplatin 27 Docetaxel 26 Cyclophosphamide 26 niraparib 25 liposomal doxorubicin 23 Topotecan 22 Etoposide 17 Doxorubicin 15 Taxes 13 apatinib 12 Letrozole 12 Immunoglobulin G 11 Filgrastim 11 Drug Therapy 11 Disulfides 11 Albumin-Bound Paclitaxel 11 fludarabine 10 fluzoparib 9 Biopsy 9 durvalumab 8 Specimen Handling 8 Nivolumab 8 Magnetic Resonance Spectroscopy 8 Cytoreduction Surgical Procedures 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00738699 2017-03-30

FAR-122

Morphotek

Phase 2 Terminated

415 enrolled 11 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡